Editing Muscle-Invasive Bladder Cancer (section)

===== <span style="color:#ff00ff">AMBASSADOR (adjuvant pembrolizumab)</span> =====
* '''Population: 702 patients with muscle-invasive urothelial carcinoma of the urinary tract or lymph node–positive disease, with or without neoadjuvant cisplatin-based therapy'''
* Randomized 1:1 to pembrolizumab (200 mg intravenously) every 3 weeks for up to 1 year or observation
* Outcomes:
** Co-Primary: disease-free survival and overall survival
* Results
** Median follow-up: ≈45 months
** Co-Primary outcome: 
*** Disease-free benefit: ≈5 months (median 45 months pembrolizumab vs. 40 months observation)
***Overall survival benefit at 3 years: -1.1% (60.8% pembrolizumab vs. 61.9% in the observation group)
* [https://pubmed.ncbi.nlm.nih.gov/39282902/ Apolo, Andrea B., et al. "Adjuvant pembrolizumab versus observation in muscle-invasive urothelial carcinoma." ''New England Journal of Medicine'' (2024).]